Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Diane Pinkard

Nurse Practitioner Knoxville, TN Nurse Practitioner

NPI 1659373710 CMS profile 10631828

9320 Kingston Pike, Knoxville, TN 37922

Open in the dashboard

General payments

$9,677

285 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane Pinkard of Knoxville, TN is reported in the CMS Open Payments database as having received $9,677 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,914 71
2024 General $1,633 50
2023 General $2,167 65
2022 General $1,439 48
2021 General $1,524 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane Pinkard
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Diane Pinkard were reported at $2,914. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Diane Pinkard Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,524 $135 $40–$426 $132
2022 $1,439 $152 $48–$470 $149
2023 $2,167 $166 $54–$529 $160
2024 $1,633 $173 $55–$556 $164
2025 $2,914 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,932 65 payments
  2. Regeneron Healthcare Solutions, Inc. $1,083 38 payments
  3. GlaxoSmithKline, LLC. $827 49 payments
  4. Genzyme Corporation $817 16 payments
  5. CSL Behring $509 15 payments
  6. Amgen Inc. $442 23 payments
  7. Genentech USA, Inc. $396 17 payments
  8. Genentech, Inc. $268 3 payments
  9. Novartis Pharmaceuticals Corporation $180 9 payments
  10. Blueprint Medicines Corporation $151 7 payments
  11. Other $1,071 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,426 280 payments
  2. Education $250 5 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE Respiratory $1,356 23 payments
  2. FASENRA $1,280 21 payments
  3. DUPIXENT Immunology $1,255 32 payments
  4. AIRSUPRA $705 13 payments
  5. DUPIXENT Inflammation And Immunology $684 26 payments
  6. Xolair $642 19 payments
  7. NUCALA $414 19 payments
  8. TRELEGY ELLIPTA $413 30 payments
  9. DUPIXENT Immunology And Inflammation $400 12 payments
  10. TEZSPIRE Inflammation $396 21 payments
  11. Other $2,244 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

339

Median for Nurse Practitioner: 389

Drug cost

$140,716

Median for Nurse Practitioner: $21,885

Branded share of claims

48.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tezspire Tezepelumab-Ekko Brand 11 $45,249
Xolair Omalizumab Brand 15 $40,604
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 57 $40,135
Breo Ellipta Fluticasone/Vilanterol Brand 15 $11,365
Fluticasone Propionate Generic 50 $905
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 43 $663
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $527
Azelastine Hcl Generic 16 $438
Montelukast Sodium Generic 24 $267
Clindamycin Hcl Generic 17 $231

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$134,256

Of which drugs: $123,128

Medicare patients

248

Average age 73

Services billed

4,434

173 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 49%
Diabetes 25%
Depression 25%
Ischemic heart disease 22%
Chronic kidney disease 17%
Osteoporosis 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 15 2,130 $63,486

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $314
  • Amgen Inc. $169
$483 11 —
DUPIXENT
  • GENZYME CORPORATION $209
  • Regeneron Healthcare Solutions, Inc. $63
$272 — —
XOLAIR
  • Genentech, Inc. $108
  • Genentech USA, Inc. $98
  • Novartis Pharmaceuticals Corporation $48
$254 15 2,130
NUCALA
  • GlaxoSmithKline, LLC. $123
$123 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record